These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26925252)

  • 21. Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study.
    Behrens F; Koehm M; Arndt U; Wittig BM; Greger G; Thaçi D; Scharbatke E; Tony HP; Burkhardt H
    J Rheumatol; 2016 Mar; 43(3):632-9. PubMed ID: 26669916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis.
    Keystone EC; Breedveld FC; Kupper H; Li Y; Florentinus S; Sainsbury I
    RMD Open; 2018; 4(1):e000637. PubMed ID: 29955381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone.
    Keystone EC; Breedveld FC; van der Heijde D; van Vollenhoven RF; Emery P; Smolen JS; Sainsbury I; Florentinus S; Kupper H; Chen K; Kavanaugh A
    RMD Open; 2017; 3(2):e000445. PubMed ID: 29018564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis.
    Benucci M; Saviola G; Baiardi P; Manfredi M; Sarzi-Puttini P; Atzeni F
    Int J Immunopathol Pharmacol; 2011; 24(1):269-74. PubMed ID: 21496415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage.
    Gallo G; Brock F; Kerkmann U; Kola B; Huizinga TW
    RMD Open; 2016; 2(1):e000186. PubMed ID: 27175292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study on the selection of DMARDs for the combination therapy with adalimumab.
    Tanaka C; Shiozawa K; Hashiramoto A; Shiozawa S
    Kobe J Med Sci; 2012 Jun; 58(2):E41-50. PubMed ID: 22972168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
    J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.
    Keystone EC; Pope JE; Thorne JC; Poulin-Costello M; Phan-Chronis K; Vieira A; Haraoui B;
    Rheumatology (Oxford); 2016 Feb; 55(2):327-34. PubMed ID: 26361879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab.
    Kimura N; Suzuki K; Takeuchi T
    Inflamm Regen; 2019; 39():5. PubMed ID: 30956738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.
    Weinblatt ME; Keystone EC; Furst DE; Kavanaugh AF; Chartash EK; Segurado OG
    Ann Rheum Dis; 2006 Jun; 65(6):753-9. PubMed ID: 16308341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
    Chen HH; Chen DY; Chen YM; Tang CH
    Patient Prefer Adherence; 2016; 10():123-34. PubMed ID: 26917952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.
    Landewé R; Østergaard M; Keystone EC; Florentinus S; Liu S; van der Heijde D
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):180-6. PubMed ID: 25073879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial.
    Lv QW; Zhang W; Shi Q; Zheng WJ; Li X; Chen H; Wu QJ; Jiang WL; Li HB; Gong L; Wei W; Liu H; Liu AJ; Jin HT; Wang JX; Liu XM; Li ZB; Liu B; Shen M; Wang Q; Wu XN; Liang D; Yin YF; Fei YY; Su JM; Zhao LD; Jiang Y; Li J; Tang FL; Zhang FC; Lipsky PE; Zhang X
    Ann Rheum Dis; 2015 Jun; 74(6):1078-86. PubMed ID: 24733191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adalimumab (Humira)--efficacy in rheumatoid arthritis treatment with particular reference to working ability].
    Grazio S
    Reumatizam; 2008; 55(2):62-7. PubMed ID: 19024278
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
    Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
    Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R; Koenig AS; Szumski A; Nab HW; Marshall L; Bananis E
    Rheumatology (Oxford); 2014 Nov; 53(11):1984-93. PubMed ID: 24907147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial.
    Kurasawa T; Nagasawa H; Kishimoto M; Amano K; Takeuchi T; Kameda H
    Mod Rheumatol; 2014 Jul; 24(4):561-6. PubMed ID: 24252035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.